GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Pharmaresearch Bio Co Ltd (XKRX:217950) » Definitions » Cash, Cash Equivalents, Marketable Securities

Pharmaresearch Bio Co (XKRX:217950) Cash, Cash Equivalents, Marketable Securities : ₩40,092 Mil (As of Dec. 2023)


View and export this data going back to 2015. Start your Free Trial

What is Pharmaresearch Bio Co Cash, Cash Equivalents, Marketable Securities?

Pharmaresearch Bio Co's quarterly cash, cash equivalents, marketable securities increased from Dec. 2021 (₩35,982.84 Mil) to Dec. 2022 (₩38,143.48 Mil) and increased from Dec. 2022 (₩38,143.48 Mil) to Dec. 2023 (₩40,091.70 Mil).

Pharmaresearch Bio Co's annual cash, cash equivalents, marketable securities increased from Dec. 2021 (₩35,982.84 Mil) to Dec. 2022 (₩38,143.48 Mil) and increased from Dec. 2022 (₩38,143.48 Mil) to Dec. 2023 (₩40,091.70 Mil).


Pharmaresearch Bio Co Cash, Cash Equivalents, Marketable Securities Historical Data

The historical data trend for Pharmaresearch Bio Co's Cash, Cash Equivalents, Marketable Securities can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Pharmaresearch Bio Co Cash, Cash Equivalents, Marketable Securities Chart

Pharmaresearch Bio Co Annual Data
Trend Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Cash, Cash Equivalents, Marketable Securities
Get a 7-Day Free Trial 4,034.29 3,976.09 35,982.84 38,143.48 40,091.70

Pharmaresearch Bio Co Semi-Annual Data
Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Cash, Cash Equivalents, Marketable Securities Get a 7-Day Free Trial 4,034.29 3,976.09 35,982.84 38,143.48 40,091.70

Pharmaresearch Bio Co Cash, Cash Equivalents, Marketable Securities Calculation

Cash and cash equivalents are the most liquid assets on the balance sheet. Cash equivalents are assets that are readily convertible into cash, such as money market holdings, short-term government bonds or Treasury bills, marketable securities and commercial paper.

Marketable Securities are very liquid securities that can be converted into cash quickly at a reasonable price.


Pharmaresearch Bio Co  (XKRX:217950) Cash, Cash Equivalents, Marketable Securities Explanation

Marketable securities are very liquid as they tend to have maturities of less than one year. Furthermore, the rate at which these securities can be bought or sold has little effect on their prices.

A high number means either:

1) The company has competitive advantage generating lots of cash

2) Just sold a business or bonds (not necessarily good)

A low stockpile of cash usually means poor to mediocre economics.

There are 3 ways to create large cash reserve.

1) Sell new bonds or equity to public

2) Sell business or asset

3) It has an ongoing business generating more cash than it burns (usually means durable competitive advantage)

When a company is suffering a short term problem, Buffett looks at cash or marketable securities to see whether it has the financial strength to ride it out.

Important: Lots of cash and marketable securities + little debt = good chance that the business will sail on through tough times.

Test to see what is creating cash by looking at past 7 yrs of balance sheets. This will reveal how the cash was created.


Pharmaresearch Bio Co Cash, Cash Equivalents, Marketable Securities Related Terms

Thank you for viewing the detailed overview of Pharmaresearch Bio Co's Cash, Cash Equivalents, Marketable Securities provided by GuruFocus.com. Please click on the following links to see related term pages.


Pharmaresearch Bio Co (XKRX:217950) Business Description

Industry
GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Pharmaresearch Bio Co Ltd (XKRX:217950) » Definitions » Cash, Cash Equivalents, Marketable Securities
Traded in Other Exchanges
N/A
Address
641-3, Saimdang-ro, Gangwon-do, Gangneung-si, KOR, 13494
Pharmaresearch Bio Co Ltd is a Korea-based biopharmaceutical company. The company is engaged in the research and development, manufacturing, sale, and marketing of biopharmaceutical products. Its product is ReNTox Injections, and Clostridium Botulinum Toxin type A is in pipeline.

Pharmaresearch Bio Co (XKRX:217950) Headlines

No Headlines